First as a consultant with The Boston Consulting Group, then as a top executive with Covance Inc., and now as the new CEO of Acurian Inc., Mark Eisenach’s mission is to help companies bring new medications to patients as quickly and efficiently as possible. Only 39, Mr. Eisenach’s influence has been profound in improving the mechanism of the clinical-trial process.
“Looking forward 20 to 30 years, healthcare is the industry where fundamental and radical change will happen with great speed,” Mr. Eisenach says. “It’s a good place to be from a career standpoint. I have always wanted to be in an industry where there is momentum, because the thing I do best is anticipate change. What drives me is being in a position to lead an organization to where it needs to be in the future.”
Throughout his career, Mr. Eisenach has made it his mission to anticipate change and build an infrastructure to adapt to the future. In all his roles at Covance — leading corporate development, marketing strategy, and ultimately launching Nexigent — and as CEO of Acurian, Mr. Eisenach has sought ways to help the healthcare industry improve efficiencies within clinical research.
Making An Impression
Faster, better, more …
A deliberate path to success
Expert on this topic
Mark Eisenach, CEO of Acurian Inc.